Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.25 USD 3.21% Market Closed
Market Cap: 598.8m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Autolus Therapeutics PLC
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Total Equity
$111.5m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Equity
$236.2m
CAGR 3-Years
324%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Equity
ÂŁ355.7m
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Equity
$831m
CAGR 3-Years
69%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Equity
ÂŁ368.8m
CAGR 3-Years
88%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Equity
ÂŁ548.2m
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
7%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
598.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 56%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Total Equity?
Total Equity
111.5m USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Total Equity amounts to 111.5m USD.

What is Autolus Therapeutics PLC's Total Equity growth rate?
Total Equity CAGR 3Y
-19%

Over the last year, the Total Equity growth was -63%. The average annual Total Equity growth rates for Autolus Therapeutics PLC have been -19% over the past three years .

Back to Top